iGan Partners Leads Significant Investment in Exact Imaging
Exact Imaging, recognized for its advanced micro-ultrasound technology aimed at urologic imaging, has secured a substantial financial boost of $10 million in funding, headed by iGan Partners. This infusion is set to catalyze the global expansion of its groundbreaking ExactVu™ prostate biopsy system, which is known for its high-resolution capabilities.
Key Highlights from Exact Imaging's Recent Developments
In the preceding year, Exact Imaging achieved notable milestones in clinical validation and market presence. One of the standout accomplishments was the publication of its pivotal OPTIMUM study in a highly regarded medical journal, which reached a significant milestone by being selected as the Editor's Choice. This study confirmed that the ExactVu™ system offers comparable accuracy to MRI-fusion biopsy methods in detecting prostate cancer, particularly in patients who have not previously undergone biopsy. The notable outcomes of this study were presented at the European Association of Urology Congress, underscoring its importance in the field.
Expansion of Commercial Operations
The company's commitment to enhancing its commercial footprint is evident through the establishment of a dedicated salesforce in North America, alongside partnerships with distribution entities in various regions including Europe and Asia. This strategic move has not only accelerated sales but also set the stage for continued growth in the upcoming year, with expectations of doubling sales figures.
Collaborative Support from iGan Partners
Since its inception, Exact Imaging has leveraged the support of its principal shareholder, iGan Partners. Co-founded by Sam Ifergan and Randy AuCoin, this relationship has been foundational, aiding the company through various stages, including intellectual property development and clinical advancement. Their collaboration reflects a strong commitment to innovative healthcare solutions.
Statements from Company Leaders
In a statement regarding the funding, Sam Ifergan expressed pride in the journey shared with Randy AuCoin and the Exact Imaging team, emphasizing the transformative potential of their work in healthcare. Randy AuCoin, the CEO of Exact Imaging, described the financing as a crucial step forward, allowing the company to broaden its reach and deliver its advanced technology to a wider audience of urologists and patients.
About Exact Imaging
Exact Imaging is at the forefront of developing high-resolution micro-ultrasound systems that enhance the precision of urologic imaging. The company's flagship product, ExactVu™, is built upon a robust portfolio of patents that facilitate timely and accurate prostate cancer detection. With a growing client base exceeding 300 across the globe, Exact Imaging is positioned to make a significant impact in the medical field.
About iGan Partners
iGan Partners is an investment firm dedicated to the healthcare sector, focusing on innovative medtech and healthcare technology ventures. Their hands-on approach, combined with extensive industry knowledge, enables them to drive advancements in technologies that significantly enhance patient care across the world.
Frequently Asked Questions
What is the purpose of the $10 million financing?
The financing will accelerate global sales and adoption of the ExactVu™ prostate biopsy system.
What notable study did Exact Imaging publish?
Exact Imaging published its landmark OPTIMUM study, confirming the effectiveness of its micro-ultrasound technology compared to MRI-fusion biopsy.
Who co-founded Exact Imaging?
Exact Imaging was co-founded by Sam Ifergan and Randy AuCoin.
What areas are Exact Imaging expanding into?
Exact Imaging is expanding its operations in North America and forming partnerships across Europe and Asia.
What is iGan Partners' focus?
iGan Partners focuses on supporting innovative healthcare technology companies to improve patient outcomes globally.
